Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of BL-M07D1 versus trastuzumab emtansine in unresectable locally advanced or metastatic HER2-positive breast cancer
CTR20240858Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BL-M07D1 in breast cancer (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Progression-free survival by BICR. Started May 2024; status: active.
02
Drugs
BL-M07D1
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20240858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240858.